Merck and the University of Cape Town to Develop a Drug Discovery Platform for Malaria

23-Nov-2015 - South Africa

Merck announced that a research agreement has been signed with the University of Cape Town (UCT) South Africa to co-develop a new R&D platform aimed at identifying new lead programs for potential treatments against malaria, with the potential to expand it to other tropical diseases.

Combining Merck’s R&D expertise and the drug discovery capabilities of the UCT Drug Discovery and Development Centre, H3D, the collaboration will conduct drug discovery research with the goal of developing anti-malarial drug candidates using Merck’s compound library.

“This strategic collaboration shows the commitment of Merck to provide access to medicines for underserved populations, while creating a potential long-term alliance for generating new drugs to treat infectious diseases,” said Beatrice Greco, Head of Malaria and Diagnostics - Global Health R&D, within the biopharmaceutical business of Merck.

Other news from the department science

More news from our other portals

All FT-IR spectrometer manufacturers at a glance